ProfileGDS5678 / 1417376_a_at
TitleAnti-VEGF and Anti-Notch treatment effect on U87 glioblastoma xenograft tumors [Mouse430_2]
OrganismMus musculus


control bevacizumab dibenzazepine GSM967852 GSM967853 GSM967854 GSM967855 GSM967856 GSM967862 GSM967863 GSM967864 GSM967865 GSM967857 GSM967858 GSM967859 GSM967860 GSM967861 82% 83% 81% 85% 77% 87% 88% 83% 82% 79% 82% 83% 83% 81% sort by agent Gene Expression Profile
Graph caption help
SampleTitleValueRank
GSM967852U87-EV human glioblastoma xenograft - Control 15.8729982
GSM967853U87-EV human glioblastoma xenograft - Control 26.0677983
GSM967854U87-EV human glioblastoma xenograft - Control 35.8197581
GSM967855U87-EV human glioblastoma xenograft - Control 46.4826585
GSM967856U87-EV human glioblastoma xenograft - Control 55.314377
GSM967862U87-EV human glioblastoma xenograft - Bevacizumab treated 16.4003387
GSM967863U87-EV human glioblastoma xenograft - Bevacizumab treated 26.7150988
GSM967864U87-EV human glioblastoma xenograft - Bevacizumab treated 36.0725983
GSM967865U87-EV human glioblastoma xenograft - Bevacizumab treated 45.9644882
GSM967857U87-EV human glioblastoma xenograft - dibenzazepine treated 15.4915879
GSM967858U87-EV human glioblastoma xenograft - dibenzazepine treated 25.9191682
GSM967859U87-EV human glioblastoma xenograft - dibenzazepine treated 36.0924183
GSM967860U87-EV human glioblastoma xenograft - dibenzazepine treated 46.0616183
GSM967861U87-EV human glioblastoma xenograft - dibenzazepine treated 55.746681